Preliminary Agenda

September 19, 2024 | Virtual & in-person at UW Tower, Seattle

8:00-9:00am – Registration / Sign-in

9:00-9:15am – Opening Remarks

Susan Ferguson, PhD, Director, UW Addictions, Drug & Alcohol Institute (ADAI)
Beatriz Carlini, PhD, Director, ADAI Cannabis Research & Education Program (CERP)

9:15-10:15am – Cannabis use and psychosis: Past, present, and future

Keynote Speaker: Marta Di Forti, MD, PhD*
King’s College of London, United Kingdom

10:15-10:30am – Break

10:30-12:30pm – Reviewing the evidence: Cannabis use, schizophrenia, and psychotic disorders

Moderator: TBD

Cannabis-induced psychosis and schizophrenia following cannabis legalization and commercialization in Canada
Daniel Myran, MD, MPH* (Ottawa Hospital Research Institute, Canada)
Understanding causality between cannabis potency and psychotic experiences through longitudinal cohorts
Lindsey A. Hines, PhD* (University of Bath, UK)
Gone to pot? The complex relationships between cannabis, cannabinoids and psychosis
Deepak Cyril D’Souza, MD* (Yale University)
Panel Q&A

12:30-1:30pm – Lunch (provided)

1:30-2:30pm – Promising clinical interventions to reduce cannabis use among at-risk consumers

Moderator: TBD

CannTalk: A brief intervention for discussing cannabis with clients experiencing psychosis.
Denise Walker, PhD (University of Washington)
Recent advances in novel approaches to reduce cannabis harms among young adults
Jason Kilmer, PhD and Katherine Walukevich-Dienst, PhD (University of Washington)

2:30-2:45pm – Break

2:45-3:30pm – Discussion panel: Opportunities and challenges to address cannabis adverse events in health care settings

Participants TBD.

3:30-4:15pm – Cannabis harm reduction policies – minimizing the role of cannabis in schizophrenia onset and progression.

4:15-4:30pm – Closing remarks and final discussion

* denotes virtual presentation